NIKA PHARMACEUTICALS, INC (NIKA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 60 120 180 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q2 '24: 156 Q1 '22 Q3 '22 Q1 '23 Q3 '23 Q2 '24

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '20: -160 Q4 '20: -8.7K Q1 '21: -5.8K Q2 '21: -3K Q3 '21: -2.7K Q4 '21: -3.3K Q1 '22: 6.3K Q2 '22: -3.2M Q3 '22: -6.3K Q4 '22: -15.1K Q1 '23: -19.6K Q2 '23: -10.1K Q3 '23: -10.1K Q4 '23: -7.3K Q1 '24: -46K Q2 '24: -22.5K Q3 '24: -8.4K Q4 '24: -12.5K Q1 '25: -12.9K Q2 '25: -18.4K Q3 '25: -8K Q4 '25: -37.1K Q1 '26: -13.4K Q2 '26: -19.7K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '20: -160 Q4 '20: -8.7K Q1 '21: 5.8K Q2 '21: 3K Q3 '21: 2.7K Q4 '21: -26.1K Q1 '22: -6.3K Q2 '22: -3.2M Q3 '22: -6.3K Q4 '22: -15.1K Q1 '23: -19.6K Q2 '23: -10.1K Q3 '23: -10.1K Q4 '23: -7.3K Q1 '24: -46K Q2 '24: -22.5K Q3 '24: -8.4K Q4 '24: -12.5K Q1 '25: -12.9K Q2 '25: -18.4K Q3 '25: -8K Q4 '25: -37.1K Q1 '26: -13.4K Q2 '26: -19.7K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-90K -60K -30K 0 30K 60K 90K Q4 '20: -5.7K Q1 '21: -5.8K Q2 '21: -3K Q3 '21: -2.7K Q4 '21: 26.1K Q1 '22: -6.3K Q2 '22: 17.1K Q3 '22: 7.8K Q4 '22: 15.1K Q1 '23: -19.6K Q2 '23: -27.8K Q3 '23: -10.1K Q4 '23: -7.3K Q1 '24: -84.3K Q2 '24: -33.9K Q3 '24: -8.4K Q4 '24: -28.3K Q1 '25: -12.9K Q2 '25: -18.5K Q3 '25: -9.3K Q4 '25: -38.9K Q1 '26: -13.4K Q2 '26: -7.6K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 400M 800M 1.2B Q1 '21: 13.2M Q2 '21: 396.1M Q3 '21: 396.1M Q1 '22: 13.2M Q2 '22: 740.6M Q3 '22: 740.6M Q1 '23: 876.1M Q2 '23: 876.1M Q3 '23: 876.1M Q1 '24: 876.1M Q2 '24: 1B Q3 '24: 1B Q1 '25: 1B Q2 '25: 1B Q3 '25: 1B Q1 '26: 1B Q2 '26: 1.1B Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 Q2 '21: 0.00 Q3 '21: 0.00 Q4 '21: 0.00 Q1 '22: 0.00 Q2 '22: 0.00 Q3 '22: 0.00 Q4 '22: 0.00 Q1 '23: 0.00 Q2 '23: 0.00 Q3 '23: 0.00 Q4 '23: 0.00 Q1 '24: 0.00 Q2 '24: 0.00 Q3 '24: 0.00 Q4 '24: 0.00 Q1 '25: 0.00 Q2 '25: 0.00 Q3 '25: 0.00 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.